Summary
Boston Scientific Corporation (BSX) announced a significant operational update in their May 21, 2010, 8-K filing. The company has received U.S. Food and Drug Administration (FDA) clearance for manufacturing changes related to several key cardiac rhythm management devices, specifically the LIVIAN™ and RENEWAL® cardiac resynchronization therapy defibrillators (CRT-Ds) and the CONFIENT™, PRIZM™, and VITALITY™ implantable cardioverter defibrillators (ICDs). Crucially, this FDA clearance allows Boston Scientific to immediately resume the distribution of these affected products within the United States. This development signifies the resolution of previous disruptions and enables the company to fully re-engage with the market for its entire portfolio of CRT-D and ICD devices in the U.S. Investors should view this as a positive step towards restoring sales momentum and addressing product availability concerns that may have impacted the company.
Key Highlights
- 1FDA clearance received for manufacturing changes on LIVIAN™ and RENEWAL® CRT-Ds.
- 2FDA clearance received for manufacturing changes on CONFIENT™, PRIZM™, and VITALITY™ ICDs.
- 3Immediate resumption of U.S. distribution for cleared CRT-D and ICD devices.
- 4Boston Scientific has now resumed U.S. distribution of all its CRT-D and ICD devices.
- 5This follows previous announcements on March 15 and April 15, 2010, regarding these actions.
- 6Indicates a resolution to previous product supply issues affecting key product lines.